Cardiovascular comorbidities of psoriasis and psoriatic arthritis

A report from the GRAPPA 2012 annual meeting

April W. Armstrong, Joel M. Gelfand, Wolf Henning Boehncke, Ehrin J. Armstrong

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.

Original languageEnglish (US)
Pages (from-to)1434-1437
Number of pages4
JournalJournal of Rheumatology
Volume40
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Psoriatic Arthritis
Psoriasis
Comorbidity
Research
Group Processes
Sweden
Insulin Resistance
Tumor Necrosis Factor-alpha
Monoclonal Antibodies

Keywords

  • Biologics
  • Cardiovascular comorbidities
  • Comparative effectiveness
  • Psoriasis
  • Psoriatic arthritis
  • Tumor necrosis factor inhibitors

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Cardiovascular comorbidities of psoriasis and psoriatic arthritis : A report from the GRAPPA 2012 annual meeting. / Armstrong, April W.; Gelfand, Joel M.; Boehncke, Wolf Henning; Armstrong, Ehrin J.

In: Journal of Rheumatology, Vol. 40, No. 8, 08.2013, p. 1434-1437.

Research output: Contribution to journalArticle

Armstrong, April W. ; Gelfand, Joel M. ; Boehncke, Wolf Henning ; Armstrong, Ehrin J. / Cardiovascular comorbidities of psoriasis and psoriatic arthritis : A report from the GRAPPA 2012 annual meeting. In: Journal of Rheumatology. 2013 ; Vol. 40, No. 8. pp. 1434-1437.
@article{8927f9ac0279452395c479ee68b9e422,
title = "Cardiovascular comorbidities of psoriasis and psoriatic arthritis: A report from the GRAPPA 2012 annual meeting",
abstract = "At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.",
keywords = "Biologics, Cardiovascular comorbidities, Comparative effectiveness, Psoriasis, Psoriatic arthritis, Tumor necrosis factor inhibitors",
author = "Armstrong, {April W.} and Gelfand, {Joel M.} and Boehncke, {Wolf Henning} and Armstrong, {Ehrin J.}",
year = "2013",
month = "8",
doi = "10.3899/jrheum.130457",
language = "English (US)",
volume = "40",
pages = "1434--1437",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "8",

}

TY - JOUR

T1 - Cardiovascular comorbidities of psoriasis and psoriatic arthritis

T2 - A report from the GRAPPA 2012 annual meeting

AU - Armstrong, April W.

AU - Gelfand, Joel M.

AU - Boehncke, Wolf Henning

AU - Armstrong, Ehrin J.

PY - 2013/8

Y1 - 2013/8

N2 - At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.

AB - At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.

KW - Biologics

KW - Cardiovascular comorbidities

KW - Comparative effectiveness

KW - Psoriasis

KW - Psoriatic arthritis

KW - Tumor necrosis factor inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84881469825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881469825&partnerID=8YFLogxK

U2 - 10.3899/jrheum.130457

DO - 10.3899/jrheum.130457

M3 - Article

VL - 40

SP - 1434

EP - 1437

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -